Kuros Biosciences Ltd (CSBTF)
9.02
0.00 (0.00%)
USD |
OTCM |
May 17, 16:00
Kuros Biosciences Enterprise Value: 315.13M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 315.13M |
| May 16, 2024 | 315.13M |
| May 15, 2024 | 315.13M |
| May 14, 2024 | 276.89M |
| May 13, 2024 | 276.89M |
| May 10, 2024 | 262.18M |
| May 09, 2024 | 259.24M |
| May 08, 2024 | 259.24M |
| May 07, 2024 | 259.24M |
| May 06, 2024 | 259.24M |
| May 03, 2024 | 244.54M |
| May 02, 2024 | 244.54M |
| May 01, 2024 | 244.54M |
| April 30, 2024 | 244.54M |
| April 29, 2024 | 316.23M |
| April 26, 2024 | 316.23M |
| April 25, 2024 | 316.23M |
| April 24, 2024 | 316.23M |
| April 23, 2024 | 316.23M |
| April 22, 2024 | 316.23M |
| April 19, 2024 | 290.50M |
| April 18, 2024 | 289.76M |
| April 17, 2024 | 289.76M |
| April 16, 2024 | 276.34M |
| April 15, 2024 | 303.00M |
| Date | Value |
|---|---|
| April 12, 2024 | 303.00M |
| April 11, 2024 | 298.95M |
| April 10, 2024 | 273.95M |
| April 09, 2024 | 237.18M |
| April 08, 2024 | 229.65M |
| April 05, 2024 | 231.67M |
| April 04, 2024 | 231.67M |
| April 03, 2024 | 224.31M |
| April 02, 2024 | 224.31M |
| April 01, 2024 | 218.80M |
| March 28, 2024 | 215.12M |
| March 27, 2024 | 213.28M |
| March 26, 2024 | 213.28M |
| March 25, 2024 | 213.28M |
| March 22, 2024 | 204.09M |
| March 21, 2024 | 204.09M |
| March 20, 2024 | 204.09M |
| March 19, 2024 | 204.09M |
| March 18, 2024 | 204.09M |
| March 15, 2024 | 204.09M |
| March 14, 2024 | 204.09M |
| March 13, 2024 | 204.09M |
| March 12, 2024 | 215.12M |
| March 11, 2024 | 204.64M |
| March 08, 2024 | 187.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-12.90M
Minimum
Dec 31 2019
316.23M
Maximum
Apr 22 2024
70.17M
Average
50.28M
Median
Aug 28 2020
Enterprise Value Benchmarks
| AC Immune SA | 198.33M |
| CRISPR Therapeutics AG | 2.666B |
| Addex Therapeutics Ltd | 4.792M |
| NLS Pharmaceutics Ltd | 7.841M |
| Molecular Partners AG | -98.31M |
Enterprise Value Related Metrics
| Earnings Yield | -4.73% |
| Normalized Earnings Yield | -4.729 |